Clinical trial · no report yet · Phase 3
ASCOLT
Aspirin for Dukes C and High Risk Dukes B Colorectal Cancers
- NCT00565708 ↗
- Unknown
- National Cancer Centre, Singapore
- 15 commentary sources found
- Standard
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| X threads | 7 | |
| YouTube | 4 | |
| Podcasts | 4 |
The trial
ClinicalTrials.gov- Official title
- Aspirin for Dukes C and High Risk Dukes B Colorectal Cancers - An International, Multi-Center, Double Blind, Randomized Placebo Controlled Phase III Trial
- Phase
- Phase 3
- Status
- Unknown
- Conditions
- Colorectal Cancer
- Interventions
- placebo; Acetylsalicylic acid
- Arms
- acetylsalicylic acid · Experimental
- Placebo · Placebo comparator
- Enrollment
- 1,587
- Primary outcomes
- Disease-free survival
- Sponsor
- National Cancer Centre, Singapore with Australasian Gastro-Intestinal Trials Group, INDOX Cancer Research Network, University of Sydney
- Start
- Dec 2008
- Primary completion
- Jun 2024 (estimated)
- Results posted
- No
- Registry record
- NCT00565708 · updated Feb 2, 2024
Publications
linked from the registry- Segelov E, Prenen H, Day D, Macintyre CR, Foo EMJ, Ali R, Wang Q, Wei X, Lopes GL Jr, Ding K, Chen G, Chia JWK, Toh HC; ASCOLT Investigators. Impact of the COVID-19 Epidemic on a Pan-Asian Academic Oncology Clinical Trial. JCO Glob Oncol. 2020 Apr;6:585-588. doi: 10.1200/GO.20.00072. No abstract available. PubMed 32293940
- Day D, Toh HC, Ali R, Foo EMJ, Simes J, Chia JWK, Segelov E; ASCOLT Investigators. Operational Challenges of an Asia-Pacific Academic Oncology Clinical Trial. JCO Glob Oncol. 2023 Jun;9:e2300040. doi: 10.1200/GO.23.00040. PubMed 37364220
- Segelov E, Li S, Li I, Mouradov D, Yip S, Day D, Jeffery M, Zielinski R, Nott L, Sun Y, Christie M, Ho GF, Chao TY, Rahman N, Foo E, Chia J, Gebski V, Toh HC, Sieber OM, Simes J. Adjuvant aspirin for colorectal cancer with PIK3CA-mutated and COX-2 overexpressed tumours: the ASCOLT translational research study and meta-analysis. EBioMedicine. 2026 Aug;130:106389. doi: 10.1016/j.ebiom.2026.106389. Epub 2026 Jul 20. PubMed 42475879
- Chia JWK, Segelov E, Deng Y, Ho GF, Wang W, Han S, Sharma A, Ding K, Chen G, Jeffery MG, Tham CK, Ahn JB, Nott L, Zielinski R, Chao TY, van Hagen T, Wei PL, Day F, Mehta S, Yau T, Peng J, Hayes TM, Li Y, Gandhi M, Foo EMJ, Rahman N, Rothwell P, Ali R, Simes J, Toh HC. Aspirin after completion of standard adjuvant therapy for colorectal cancer (ASCOLT): an international, multicentre, phase 3, randomised, double-blind, placebo-controlled trial. Lancet Gastroenterol Hepatol. 2025 Mar;10(3):198-209. doi: 10.1016/S2468-1253(24)00387-X. Epub 2025 Jan 14. PubMed 39824200
- Ali R, Toh HC, Chia WK; ASCOLT Trial Investigators. The utility of Aspirin in Dukes C and High Risk Dukes B Colorectal cancer--the ASCOLT study: study protocol for a randomized controlled trial. Trials. 2011 Dec 14;12:261. doi: 10.1186/1745-6215-12-261. PubMed 22168568